SUMMARY ANSWER: E-MSCs can acquire endothelial markers and function in a direct co-culture system with HUVECs.
Introduction
Endometriosis is a chronic and oestrogen-dependent disease characterized by the presence of ectopic endometrial tissue, comprising glands and stroma, outside the uterine cavity (Bulun, 2009; Giudice, 2010) . A number of studies supported the presence of rare clonogenic epithelial and stromal cells with stem cell characteristics in the human endometrium (Chan et al., 2004; Chan and Gargett, 2006; Gargett, 2006; Gargett et al., 2009 ), thought to be physiologically involved in the cyclic endometrial regeneration after menstruation (Schwab et al., 2005; Masuda et al., 2010; Gargett et al., 2016) . Endometrial mesenchymal stromal cells (E-MSCs), in particular, are clonogenic mesenchymal like cells (Gargett et al., 2009 ) expressing pericyte markers (Berger et al., 2005; Spitzer et al., 2012) , and localized in the perivascular space of endometrial small vessels (Schwab and Gargett, 2007) .
Clonogenic E-MSCs have also been identified in cultures derived from ovarian endometriotic lesions (Chan et al., 2011; Kao et al., 2011) . Ectopic E-MSCs showed a higher proliferation, migration and angiogenic ability than eutopic E-MSCs (Kao et al., 2011) . It is possible that E-MSCs that are abnormally shed during menstruation migrate into the peritoneal cavity and consequently proliferate, invade and generate endometriotic implants (Starzinski-Powitz et al., 2001; Leyendecker et al., 2002; Sasson and Taylor, 2008) . In this context, the role of E-MSCs mainly appears to be the formation of the endometrial stromal vascular tissue and the support of tissue growth and vascularization through secretion of pro-angiogenic and growth supporting factors (Gargett et al., 2014) . In addition, clonally purified sushi domain containing 2 (SUSD2) + EMSCs were shown to acquire endothelial marker expression and to integrate into renal blood vessels after xenograft under the kidney capsule, underlying an endothelial differentiative ability (Masuda et al., 2012) . In addition, circulating endothelial progenitor cells may contribute to the de novo vessel formation in endometriosis (Du and Taylor, 2007; Laschke et al., 2011) . However, the endometrial angiogenic process is mainly driven by recruitment of endothelial cells by surrounding tissues (Nisolle et al., 1993; Maas et al., 2001; Laschke and Menger, 2007) . The interaction of stromal and endothelial cells within endometrial angiogenesis has not been investigated yet. Vascular endothelial growth factor (VEGF) appears to be the main regulator of endometrial angiogenesis. Indeed, VEGF polymorphisms seem to be associated with the risk of endometriosis (Li et al., 2013) . In addition, increased levels of VEGF were found in the peritoneal fluid of women with endometriosis and in ectopic endometrial tissue, suggesting the relevance of a pro-angiogenic microenvironment in the development of the endometriotic implant (Donnez et al., 1998; McLaren, 2000; Bourlev et al., 2006) . The use of anti-angiogenic drugs therefore appears as a possible therapeutic strategy against endometriosis (Hull et al., 2003; Taylor et al., 2009; Pittatore et al., 2014) . VEGF targeting using VEGF neutralizing antibodies or tyrosine kinase inhibitors effectively reduced growth of endometriotic implants, microvessel density and VEGF expression in models of endometriosis in mice, rats and monkeys (Park et al., 2004; Van Langendonckt et al., 2008; Ozer et al., 2013) . Similarly, interfering with VEGF-VEGF receptor 2 (VEGFR2) signalling using a dopamine agonist displayed an anti-angiogenic effect in experimental endometriosis. Furthermore, we previously demonstrated that the tyrosine kinase inhibitor Sorafenib affected the angiogenic potential of ectopic E-MSCs in vitro and reversed their increased VEGF release .
In the present study, we aimed to investigate the angiogenic process and to set up an in vitro model of endometriosis using stromal mesenchymal cells isolated from ovarian endometrial tissue. We found that E-MSCs acquired endothelial markers and contributed to in vitro tubulogenesis during co-culture with human umbilical vein endothelial cells (HUVEC) cells. Finally, we evaluated the effect of the dopamine antagonist Cabergoline, also reported to affect VEGF signalling (NovellaMaestre et al., 2009 (NovellaMaestre et al., , 2012 , in this model.
Materials and Methods

Patients
The cell lines were derived from samples obtained from nine patients receiving surgery for treatment of ovarian endometriosis in the Department of Surgical Sciences, University of Torino, between November 2013 and April 2015 after approval by the Ethics Review Board. Preoperative written informed consent was obtained from each patient.
E-MSC isolation and culture
Two samples were collected from the same patient with endometriosis: one of eutopic tissue by gently scraping the endometrium and one of ectopic implant by surgical biopsy of the inner wall of the ovarian endometrial tissue. The tissues were immediately placed in a sterile tissue culture dish and dissected into small fragments using a scalpel blade in a sterile laminar flow hood. The obtained fragments were then enzymatically processed with 0.1% Type I Collagenase (Sigma-Aldrich, St. Louis, MO, USA) for 30 min in a 37°C incubator. Later, cell aggregates were filtered through 60-mm and 120-mm meshes. Cells were seeded at a density of 1 × 10 4 /cm 2 viable cells (80% viable cells determined by trypan blue assay) in EBM: medium plus supplement kit without serum addition (Lonza, Basel, Switzerland) previously described for E-MSC isolation . Dead cells were poured off 72 h later and, after 5-7 days, cell clones were typically observed. Confluence was achieved 10-14 days after plating. Cells were passaged at confluence and after 2-3 days in the subsequent passages. The E-MSCs obtained (eutopic E-MSCs, n = 9; ectopic E-MSCs, n = 9) were cultured for 12 passages as maximum to test the proliferative capacity typical of MSCs.
All the experiments were performed between passages 3 and 8. Eutopic and ectopic E-MSCs were used at the same cell passage.
Flow cytometric analysis
Cytometric analysis was performed using FACScan (Becton Dickinson, San Jose, CA, USA) as previously described (Bruno et al., 2009 
Real-time PCR analysis
Gene expression (mRNA level) was analysed by quantitative real time RT-PCR (qRT-PCR) with Applied Biosystems StepOne (Applied Biosystems, Foster City, CA, USA), as previously described 
HUVEC culture and generation of GFP positive cells
HUVECs isolated from the umbilical vein vascular wall were seeded on fibronectin-coated plates and cultured in endothelial cell basal medium with an EGM-MV kit (Lonza; containing epidermal growth factor, hydrocortisone, bovine brain extract) and 10% foetal calf serum in an incubator (37°C, 5% CO 2 atmosphere). Cell confluence was monitored by phasecontrast microscopy. For green fluorescent protein (GFP) insertion a pGIPZ lentiviral vector (Open Biosystems, Lafayette, CO, USA) was used. The 293 T cell line was transfected with the construct using the ViraPower Packaging Mix (Life Technologies) for lentivirus production. After titering the lentiviral stock, HUVECs were transduced with lentiviral particles following the manufacturer's instructions. Cells were selected by Puromycin (ThermoFisher, Waltham, MA, USA) (1000 ng/ml), and antibiotic-resistant cells were expanded. Cell infection was evaluated by GFP + >98%, as assessed by FACS analysis.
Co-culture systems
A co-culture system was established in direct contact or by using transwells (1 µm pore, Falcon, Becton Dickinson) in T75 flasks or 6-well plates (Corning Incorporated, NY, USA), respectively. HUVECs and E-MSCs were seeded into the two compartments of the culture wells at a ratio of 1:1 (75 × 10 3 /cell line). For direct co-culture, a mix of HUVEC-E-MSC suspension at a ratio of 1:1 (3 × 10 5 cells/line) was seeded in a T75 flask and in EBM in a humidified incubator (5% CO 2 , 37°C) for 48 h. HUVECs and E-MSCs were also cultured alone and used as control.
Tubulogenic assay
In vitro formation of capillary-like structures was studied on growth factor-reduced Matrigel (BD Biosciences) in 24-well plates. Eutopic and ectopic E-MSCs were stained with DIL (1,1′-Dioctadecyl-3,3,3′,3′-Tetramethylindocarbocyanine Perchlorate) (Life Technologies) according to manufacturer's instructions, and plated 1:1 with HUVEC-GFP on growth factor-reduced Matrigel (BD Biosciences) for in vitro formation of capillary-like structures. DIL staining was assessed by flow cytometry at 0, 24 and 48 h (not shown). Cells (6 × 10 4 cells per well) were mixed and seeded onto Matrigel-coated wells in endothelial cell basal medium plus VEGF at 10 ng/ml final concentration. Cell organization onto Matrigel was imaged after 24-48 h with a Nikon Eclipse Ti inverted microscope using a Nikon Plan 10X/0.10 objective and cells were kept in the incubator at 37°C and 5% CO 2 throughout the experiment (OKOLab, Napoli, Italy).
Immunofluorescence
Immunofluorescence was performed on chamber slides (Sigma) on which cells were fixed in 4% paraformaldehyde containing 2% sucrose for 15 min at 4°C, permeabilized with 0.1% Triton X-100 (Sigma) for 8 min at 4°C, and then incubated overnight at 4°C with the appropriate antibodies. Anti-CD31 antibody (Biomeda, Foster City, CA, USA 1:200) was used. Primary antibody was detected using anti-mouse secondary antibody conjugated with Texas Red (ThermoFisher, 1:5000). DAPI dye (Sigma) was added for nuclear staining, and imaging was performed using an LSM5 Pascal confocal microscope (Carl Zeiss International, Oberkochen, Germany). Substitution with an unrelated rabbit serum or mouse IgG served as negative control.
Cell sorting
Cells were stained with anti-CD31 antibody (Miltenyi Biotec) and sorted using a BD FACSAria III, equipped with the BD FACSDiva software v. 7.0 (Becton Dickinson). At least 10 000 events per sample were acquired, obtaining three populations from each co-culture (GFP 
Drugs and reagents
Sunitinib malate (Sigma-Aldrich) was resuspended in dimethylsulphoxide (DMSO) to a final concentration of 10 mM and stored at 4°C. Sorafenib (Bayer Pharmaceuticals, Leverkusen, Germany) was resuspended in DMSO to a stock concentration of 10 mM and stored at −20°C. Bevacizumab, 25 mg/ml (Genentech, San Francisco, CA, USA) was stored at 4°C. Cabergoline powder 10 mg (Sigma-Aldrich) was dissolved in 885 µl of DMSO to a stock concentration of 25 mM and stored at −20°C. Sunitinib and Sorafenib were diluted 1:100 000 in the culture medium (final concentration 0.1 µM), Bevacizumab was diluted 1:1000 (final concentration 25 µg/ml) and Cabergoline was diluted 1:1000 (final concentration 25 µM). All the drugs were administered for 24 h during cell cultures.
Statistical analysis
Results were expressed as mean ± SD and analysed with GraphPad Prism V5 (GraphPad Software Inc., San Diego, CA, USA). Data were tested for normality using the Shapiro-Wilk test. Differences in mRNA expression level among groups were investigated using non-parametric analysis by Kruskal-Wallis test with Dunn's post test. Eutopic and ectopic cell lines of the same patient were compared using a Wilcoxon test where indicated.
Significance was set at P < 0.05.
Results
Eutopic and ectopic E-MSC characterization
In order to study the angiogenic potential of the mesenchymal like population present in eutopic and ectopic endometrial tissue, we cultured stromal cells from eutopic and ectopic tissues derived from patients affected by ovarian endometriosis (n = 9). The clinical characteristics of the patient population enrolled for this study are listed in Table I . The obtained cell lines were characterized for their fibroblastic phenotype, adherence to plastic and expression of mesenchymal markers (Table II and Fig. 1 ). As shown in Fig. 1 , E-MSCs expressed CD44, CD73, CD105, CD29 and CD90. Eutopic and ectopic E-MSCs showed a similar expression of mesenchymal markers. PDGFRb and SUSD2, considered more specific markers for endometriotic mesenchymal stem cells (Gargett et al., 2016) , were expressed by a large fraction of cells. These characteristics suggest that, as reported (Bianco et al., 2013; Gargett et al., 2016) , E-MSCs represent a heterogenic population of mesenchymal stem cells and stromal fibroblast, sharing a number of markers and functions. CD146, a marker of both mesenchymal and endothelial cells (Wang and Yan, 2013) , was significantly higher in the ectopic cell line. As shown in Table II , both eutopic and ectopic E-MSCs did not express markers of endothelial/hemopoietic cells such as CD34 and CD45, CD31, VEGFR2, Tie2 and Ve-Cadherin. The presence of epithelial cell contamination was excluded by lack of the epithelial marker EPCAM in both cell lines. These data indicate that ectopic E-MSCs isolated from ovarian endometrial tissue have a mesenchymal phenotype similar to those isolated from peritoneal endometriosis .
Endothelial potential of eutopic and ectopic E-MSCs
We subsequently evaluated the endothelial angiogenic ability of eutopic and ectopic E-MSCs by an endothelial in vitro differentiation. We first characterized E-MSCs for the expression of endothelial markers. At the basal level, the cells expressed minimal levels of CD31 ( Fig. 2 and Table II ). Endothelial cells (HUVECs) were used as positive control (Table II) . For the in vitro differentiation, the cells were seeded on attachment factor coated dishes and cultured in ENDO-GRO media plus VEGF (10 ng/ml), previously reported to induce endothelial differentiation of mesenchymal cells (Brossa et al., 2015) . After 14 days of differentiation, we observed the acquirement of CD31 expression ( Fig. 2A) , as previously reported (Masuda et al., 2012) , confirming that E-MSCs may differentiate into endothelial cells.
To mimic the pericyte-endothelial interaction in endometriosis, we analyzed the endothelial differentiative ability of both eutopic and ectopic E-MSCs in a co-culture model with endothelial cells, using either an indirect stimulation, where HUVEC cells were plated on a trans-well, without a direct contact with E-MSCs or a direct co-plating of HUVECs and E-MSCs. The HUVEC cells were traced by GFP expression (>98% expression in all experiments). In the indirect setting, the presence of HUVECs did not affect the expression of the endothelial marker CD31 in both eutopic and ectopic E-MSCs for up to 7 days co-culture (Fig. 2B) . In contrast, the direct co-culture of E-MSCs and HUVECs induced the presence of a population acquiring high CD31 expression Figure 1 Expression of mesenchymal and hematopoietic markers by human eutopic and ectopic E-MSCs. Representative FACS analysis of eutopic and ectopic endometrial mesenchymal stromal cells (E-MSCs) are shown. The filled area shows binding of the specific antibody, and the grey line shows the isotypic control. All ectopic and eutopic E-MSC lines, obtained from each patient (n = 9), were characterized and showed similar marker expression. by GFP-negative E-MSCs, as observed by FACS analysis using a selective gating strategy and by immunofluorescence images (Figs 2B, C and 3A) . This effect was observed as early as 48 h. No further increase was observed at longer co-culture times (4 and 7 days, not shown).
Furthermore, in order to analyze the functional potential of E-MSC-HUVEC interaction, we set up a tube-forming assay onto Matrigel. As shown by Fig. 3B , E-MSCs could not organize into elongated tubular-like structures, as seen in HUVEC cells. When E-MSCs were plated together with HUVECs on Matrigel, both cells contributed to the formation of tube-like structures (Fig. 3B) . These data indicate that the direct contact between E-MSCs and HUVECs may influence the differentiating potential of E-MSCs into endothelial cells and their functional involvement.
Isolation and analysis of the CD31 + E-MSC population
In order to analyze the nature of the E-MSC population expressing CD31 after HUVEC co-culture, we isolated GFP neg /CD31 + cells using a cell-sorter and we analyzed their gene expression compared to GFP + HUVECs (positive control), to the basal cells (not in co-culture) and to GFP neg /CD31 neg E-MSCs after co-culture ( Fig. 4A and B and Supplementary Fig. S1 ). Real Time qRT-PCR confirmed the increase in the expression of CD31 mRNA in the sorted CD31 + E-MSCs compared to the basal and to CD31 neg E-MSCs after co-culture (P < 0.05).
In parallel, we observed a significant increase in VEGFR2 and VeCadherin expression in both eutopic and ectopic CD31 + E-MSC lines.
However, Tie-2 expression was increased only in the ectopic CD31 + E-MSCs with respect to basal and to CD31 neg cells. No significant differences were observed in the expression of VEGF in the different cell fractions (Fig. 4B) . Moreover, the expression of the mesenchymal genes c-Myc and Vimentin, also expressed by HUVEC cells, was unchanged ( Supplementary Fig. S1 ). N-Cadherin and SUSD2, E-MSC markers, were expressed at higher levels in E-MSCs than in HUVECs, but they did not show significant variations when comparing CD31 + and CD31 neg cells (Supplementary Fig. S1 ). Comparing the expression levels of endothelial markers in the GFP neg /CD31 + cells from eutopic and ectopic E-MSCs, whereas Tie2 was significantly increased in the ectopic cell line (P < 0.05) no difference was observed for CD31, VEGFR2 and Ve-Cadherin. Altogether these data reveal that a subpopulation of E-MSC may acquire an endothelial-like gene expression implying a progressive endothelial differentiation.
Effect of cabergoline treatment on the endothelial potential of E-MSCs
In order to evaluate the efficacy of anti-angiogenic drugs in limiting the endothelial differentiation of E-MSCs during the direct co-culture with HUVECs, we tested the effect of Sorafenib, Sunitinib, Bevacizumab treatment, used at not toxic concentrations as previously described (Fiorio Pla et al., 2014; Brossa et al., 2015) . No significant reduction in the percentage of CD31 expressing E-MSCs as evaluated by FACS analysis after Sorafenib, Sunitinib or Bevacizumab treatment was obtained (data not shown). We subsequently focused on Cabergoline, a dopamine receptor 2 agonist also shown to impact neo-angiogenesis and endometrial lesions (Novella-Maestre et al., 2009 , 2010 . Cabergoline was administered after 24 h of co-culture. We observed that the increase in CD31 expression obtained after co-culture was significantly reduced by a 24-h treatment with Cabergoline 25 μM in both eutopic and ectopic cell line ( Fig. 5A and B) . In contrast, Cabergoline did not affect the incorporation of E-MSCs in HUVEC tubular structures (Fig. 5C ). It could be speculated that VEGF signalling is only partly involved in the early endothelial differentiation observed and that this is largely dependent on endothelial-stromal contact.
Discussion
In the present study, we focused our attention on the angiogenic potential of human E-MSCs isolated from eutopic and ectopic endometrial tissue. We found that endothelial co-culture promoted the acquirement of endothelial markers and function, and that this required a direct cell-to-cell contact. In addition, Cabergoline treatment partly inhibited this process. E-MSCs are mesenchymal-like cells localized in the perivascular space of endometrial small vessels (Schwab and Gargett, 2007) , and possibly involved in support of angiogenesis and endothelial integrity. We also previously found that stromal cells isolated from ectopic endometrial lesions expressed higher levels of VEGF and hypoxia inducible factor with respect to those isolated from eutopic endometrial tissue, which may in turn promote angiogenesis . This result was confirmed in the present study using ectopic E-MSCs from ovarian endometrial tissue. E-MSCs were previously shown to differentiate into endothelial cells when cultured within endothelial growth factors (Oswald et al., 2004; Masuda et al., 2012) . We also found in the present study, the acquisition of CD31 by a fraction of the cells after 14 days of culture with endothelial differentiating medium. Moreover, it was recently shown that E-MSCs are able to acquire endothelial markers (CD31, Ve-cadherin and VEGFR2) when plated onto a nanofibrous scaffold in the presence of angiogenic factors, suggesting their potential angiogenic property in selected culture conditions (Shamosi et al., 2016) .
To understand if the interaction with endothelium could cause an activation of the differentiative programme of E-MSCs, we co-cultured them with HUVECs. As shown by both FACS and immunofluorescence images, we demonstrated that E-MSCs could acquire an endothelial phenotype as soon as after 48 h and participate in vessel organization in vitro together with endothelial cells. Eutopic and ectopic E-MSCs showed a similar behaviour and acquisition of endothelial markers. However, the ectopic E-MSCs specifically increased Tie2, the angiopoietin-2 receptor that could possibly represent a specific ectopic E-MSC marker. The identification of a subpopulation, around 10% of cells, acquiring high levels of CD31 and expressing endothelial markers could be dependent on the heterogeneity of E-MSCs, possibly comprising both mesenchymal stem cells and stromal fibroblasts. The basal characterization and the expression of SUSD2 indicated a fraction of mesenchymal stem cell population larger than 10% in our culture. Indeed, these populations represent a continuum, as the mesenchymal stem population may spontaneously differentiate into fibroblasts, and they share several functions (Barragan et al., 2016) . The absence of a pure mesenchymal stem population could limit the process of endothelial differentiation.
Of interest, this rapid acquirement of the endothelial phenotype appears to be due to cell-to-cell interactions, possibly involving adhesionrelated mechanisms, rather than growth factor release, as no differentiation was observed with an indirect co-culture. In addition, the use of a VEGF-specific inhibitor was unable to reduce the acquisition of endothelial markers. These data suggest that E-MSCs might be involved in the vessel formation, by an interaction with endothelial cells. Further studies are required to identify the contact-activated pathways involved. These data confirm the direct functional contribution of E-MSCs to the endothelial microenvironment and suggest that these cells may play a role in the pathogenesis of gynaecological diseases, such as endometriosis and adenomyosis, due to inappropriate shedding of stem cells or alterations in the stem cell niche (Gargett, 2006) . It is also conceivable that a fraction of E-MSCs could contribute to angiogenesis and vessel formation through their pericyte/perivascular role in ectopic vessels in addition to their ability to differentiate into endothelial cells. However, >80% of blood vessels observed in endometriosis implants are pericyte-free (Hull et al., 2003) .
Angiogenesis is a fundamental process for the physiological growth of the endometrium, as well as in the establishment of endometriosis (Donnez et al., 1998; McLaren, 2000; Du and Taylor, 2007; Laschke and Menger, 2007) . Indeed different studies suggest the therapeutic efficacy of anti-angiogenic therapy targeting VEGF for endometriosis eradication (Hull et al., 2003; Nap et al., 2004; Taylor et al., 2009; Pittatore et al., 2014) . However, anti-angiogenic drugs currently available on the market are quite expensive and are mainly used in oncology, causing relevant undesired effects. However, the dopamine agonist Cabergoline, which has been used for several years to block lactation or treat hyper-prolactinemia, appears as an easier and more 2 (VEGFR2), TEK receptor tyrosine kinase (Tie2), vascular endothelial Cadherin (Ve-Cadherin) and vascular endothelial growth factor (VEGF) in E-MSCs (basal), and in sorted GFP neg /CD31 + and GFP neg /CD31 neg E-MSCs after direct co-culture with HUVECs. HUVECs were used as positive control. Data were normalized to TATA binding protein (TBP) mRNA and to 1 for HUVECs and expressed as relative quantification (RQ). Data are mean ± SD of four different cell lines. *P < 0.05 Basal versus CD31 + ; § P < 0.05 CD31 + versus CD31 − (Kruskal-Wallis test).
practical option. The mechanism responsible for the anti-angiogenic effect of Cabergoline is still unclear, possibly relying on its ability to block the VEGF-VEGFR2 interaction (Novella-Maestre et al., 2009). In our study, Cabergoline but not other anti-VEGF drugs impaired, in part, endothelial differentiation. However, it did not affect the ability of E-MSCs to organize into tubular structures. These data support a prominent role for stromal-endothelial interactions rather than for VEGF-mediated signals in the early endothelial differentiation of EMSCs (at 48 h) and suggest a VEGF-independent effect of Cabergoline. At variance, VEGF could be important as a later signal, as VEGF addition to the culture medium promoted endothelial differentiation after 14 days. Therefore, strategies aimed to inhibit endometriosis should be considered in the context of the different cell types present in the ectopic microenvironment.
In conclusion, our data suggest that E-MSCs could be driven by the surrounding endothelial cells to differentiate and to take part in the formation of endothelium and new blood vessels. Moreover, we propose a simple cell culture system that closely mimics the cellular complexity typical of endometriotic tissues in vivo. This system might be useful for testing novel strategies for treatment.
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